Zydus Lifesciences (formerly Cadila Healthcare) and Sunshine Healthcare Lanka Ltd have announced a joint venture to establish a pharmaceutical manufacturing facility in Sri Lanka with an investment of $20 million. The announcement was made in June 2026, according to company filings and media reports.
The facility will be located in the Board of Investment (BOI) zone in Sri Lanka and is expected to produce a range of pharmaceutical products, including tablets, capsules, and injectables, to cater to both local and export markets. The joint venture will be held 70% by Zydus and 30% by Sunshine Healthcare.
This investment aligns with Sri Lanka's efforts to boost domestic pharmaceutical production and reduce reliance on imports. The plant is projected to create approximately 300 jobs and is expected to become operational within 18-24 months, pending regulatory approvals.
Zydus Lifesciences, an Indian multinational, has a presence in over 50 countries. Sunshine Healthcare is a leading Sri Lankan healthcare company. The partnership aims to leverage Zydus's manufacturing expertise and Sunshine's local market knowledge.
